State of the Science and Future Directions for Liquid Biopsies in Drug Development

Author:

Narayan Preeti1,Ghosh Soma2,Philip Reena2,Barrett J. Carl3,McCormack Robert T.4,Odegaard Justin I.5,Oxnard Geoffrey R.6,Pracht Laurel J.7,Williams P. Mickey8,Kelloff Gary J.9,Beaver Julia A.1

Affiliation:

1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

2. Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

3. AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA

4. RMCC Consulting, LLC, Chester, New Jersey, USA

5. Guardant Health, Redwood City, California, USA

6. Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA

7. Patient Advocate, National Cancer Institute, Bethesda, Maryland, USA

8. Frederick National Laboratories for Cancer Research, Frederick, Maryland, USA

9. National Cancer Institute, Bethesda, Maryland, USA

Abstract

With advances in precision oncology, liquid biopsies have shown promise as a minimally invasive means to diagnose cancer and guide treatment decisions. This commentary presents an assessment of the potential and the challenges of widespread use of liquid biopsy testing, based on the 2019 Accelerating Anticancer Agent Development Workshop.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3